Muhammad F Samudra1, Imam Rosadi2,3, Irsyah Afini2, Tias Widyastuti2, Siti Sobariah2, Melinda Remelia4,5, Riris L Puspitasari1, Iis Rosliana2, Tri I Tunggadewi6. 1. Biology, Universitas Al Azhar Indonesia, Jakarta, Indonesia. 2. HayandraLab, Yayasan Hayandra Peduli, Jakarta, Indonesia. 3. Master Degree of Biotechnology, Institut Teknologi Bandung, Bandung, Indonesia. 4. Doctoral Program of Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. 5. Department of Basic Biomedicine, Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia. 6. Animal Hospital Faculty of Veterinary Medicine, Bogor Agricultural Institute, Bogor, Indonesia.
Abstract
BACKGROUND: Adipose-derived stem cells (ADSCs) improve wound healing owing to their angiogenic potency. However, the production of large quantities of ADSCs for clinical applications is laborious. In this study, the efficacy of the stromal vascular fraction (SVF; non-expanded ADSCs) combined with platelet-rich plasma (PRP) which contains abundant growth factors, for wound healing was evaluated using an animal model. METHODS: PRP from venous blood and SVF from lipoaspirates were harvested from six donors. PRP, SVF, SVF + PRP, and saline solution as a negative control were injected to second degree burn wounds in the backs of 24 male Sprague-Dawley rats. On the seventh day after injection, rats were euthanized and wounds were analyzed microscopically and macroscopically. RESULTS: Wounds closed faster in the SVF + PRP group than in the control group or PRP or SVF alone groups, with less inflammation, prominent signs of re-epithelization, more skin appendages and blood vessels, and a higher rate of hair growth. No infection or rat death occurred during the trial. CONCLUSIONS: The combination of SVF and PRP may provide an additive stimulatory effect to support angiogenesis and accelerate the wound healing process; accordingly, this combination is a potential alternative to ADSC treatment.
BACKGROUND: Adipose-derived stem cells (ADSCs) improve wound healing owing to their angiogenic potency. However, the production of large quantities of ADSCs for clinical applications is laborious. In this study, the efficacy of the stromal vascular fraction (SVF; non-expanded ADSCs) combined with platelet-rich plasma (PRP) which contains abundant growth factors, for wound healing was evaluated using an animal model. METHODS: PRP from venous blood and SVF from lipoaspirates were harvested from six donors. PRP, SVF, SVF + PRP, and saline solution as a negative control were injected to second degree burn wounds in the backs of 24 male Sprague-Dawley rats. On the seventh day after injection, rats were euthanized and wounds were analyzed microscopically and macroscopically. RESULTS: Wounds closed faster in the SVF + PRP group than in the control group or PRP or SVF alone groups, with less inflammation, prominent signs of re-epithelization, more skin appendages and blood vessels, and a higher rate of hair growth. No infection or rat death occurred during the trial. CONCLUSIONS: The combination of SVF and PRP may provide an additive stimulatory effect to support angiogenesis and accelerate the wound healing process; accordingly, this combination is a potential alternative to ADSC treatment.
Authors: Xianjie Zhang; Xiaofei Wei; Lixin Liu; Guy P Marti; Mohammed S Ghanamah; Muhammad J Arshad; Lori Strom; Robert Spence; James Jeng; Stephen Milner; John W Harmon; Gregg L Semenza Journal: Arch Surg Date: 2010-03
Authors: Pietro Gentile; Augusto Orlandi; Maria Giovanna Scioli; Camilla Di Pasquali; Ilaria Bocchini; Valerio Cervelli Journal: Stem Cells Transl Med Date: 2012-02-22 Impact factor: 6.940
Authors: Ann Hoeben; Bart Landuyt; Martin S Highley; Hans Wildiers; Allan T Van Oosterom; Ernst A De Bruijn Journal: Pharmacol Rev Date: 2004-12 Impact factor: 25.468
Authors: Neil H Riordan; Thomas E Ichim; Wei-Ping Min; Hao Wang; Fabio Solano; Fabian Lara; Miguel Alfaro; Jorge Paz Rodriguez; Robert J Harman; Amit N Patel; Michael P Murphy; Roland R Lee; Boris Minev Journal: J Transl Med Date: 2009-04-24 Impact factor: 5.531